Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.
We conducted a randomised clinical trial on 211 patients with small-cell lung cancer in complete remission (CR). The aim of this trial was to evaluate the effect of prophylactic cranial irradiation (PCI) on overall survival. Eligible patients were randomly assigned to receive either PCI (100 patients) or no PCI (111 patients). Each centre was allowed to use its own PCI protocol as long as the total dose was within the range of 24-30 Gy and delivered in less than 3 weeks with fractions of 3 Gy or less. The mean follow-up is 5 years. The survival curves do not differ significantly (P = 0.25) between the two groups. The 4-year overall survival rate (95% confidence interval) is 22% [15-32%] in the PCI group versus 16% [10-25%] in the control group. The relative risk of death in the PCI group compared to the control group is 0.84 (95% CI = [0.62-1.13]). The incidence of brain metastasis is lower in the PCI group, but the difference is not statistically significant (P = 0.14). The 4-year cumulative rate of brain metastasis is 44% [32-57%] in the PCI group compared to 51% [38-63%] in the control group. In conclusion, in this study, which had to be closed prematurely, no significant difference was found in terms of the incidence of brain metastases nor in survival.
Laplanche
A
A
Département de Biostatistique et d'Epidémiologie, Institut Gustave Roussy, Villejuif, France. laplanch@igr.fr
Monnet
I
I
Santos-Miranda
J A
JA
Bardet
E
E
Le Péchoux
C
C
Tarayre
M
M
Arriagada
R
R
D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000517:prevention & control* / Q000532:radiotherapy; D016371:Cranial Irradiation; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000517:prevention & control; D012074:Remission Induction; D055502:Secondary Prevention